Yesterday, Professor Artur Schmidtchen presented our latest findings at the 2024 European Academy of Dermatology and Venereology Congress in Amsterdam, Europe’s largest international meeting focused on dermatology and venereology. The congress remains a key platform for sharing knowledge and fostering innovation, and Xinnate was proud to showcase its research before a global audience.
Professor Schmidtchen’s presentation highlighted new data on TCP-25 gel, which demonstrated a dual-action mechanism for bacterial control and inflammation reduction in epidermal wounds. The results showed that TCP-25 gel not only reduced bacterial levels while preserving beneficial skin flora but also exhibited anti-inflammatory effects, contributing to improved wound healing.
About Xinnate
Xinnate is a pharmaceutical development company that develops novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbes and the complex interplay of inflammatory responses. Xinnate runs an ambitious development program to transform lives for patients with high unmet medical need in inflammatory skin conditions, wounds and surgical procedures. The company´s first drug candidate TCP-25 gel, is a novel pharmaceutical based on a synthetically manufactured peptide, TCP-25.
For more information
Helene Hartman, CEO
Helene.hartmann@xinnate.com
Phone: +46 (0)72-512 03 12